Reuters AstraZeneca's drug, Lynparza, helped women with ovarian cancer live longer without worsening their disease. Deutsche Bank analysts said this could represent around a $1 billion incremental sales opportunity for the drug, on top of its existing approved second- and third-line use, while Jefferies put it at $1.6 billion. The drug is far ahead of any competition, with its closest competitor being Tesaro, expected to report results next year. LONDON
AstraZeneca and Merck are gearing up for a $1 billion boost after their cancer drug passed a key trial (AZN, MRK)
Business Insider - 27 Jun 2018 16:46
Reuters AstraZeneca's drug, Lynparza, helped women with ovarian cancer live longer without worsening their disease. Deutsche Bank analysts said this could represent around a $1 billion incremental sales opportunity for the drug, on top of its existing approved second- and third-line use, while Jefferies put it at $1.6 billion. The drug is far ahead of any competition, with its closest competitor being Tesaro, expected to report results next year. LONDON
Share this Article
Recommended